Clinical trials: GAD
MDD, Anxiety Disorders
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression coexisting with generalized anxiety disorder.
- Trial name
- RECONNECT (NCT04220996)
- Testing
- Vortioxetine
- Where
- 21 sites in Estonia, France and 4 more
- Volunteers
- 100 people
- Sponsor
- H. Lundbeck A/S
Therapeutic Drug Monitoring (TDM), Menopause
Escitalopram Plasma Concentrations in Premenopausal and Postmenopausal Women
This observational cross-sectional case-control study aims to evaluate the effects of menopausal status on escitalopram metabolism in women.
- Conditions
- Therapeutic Drug Monitoring (TDM), Menopause, Depression - Major Depressive Disorder, General Anxiety Disorder
- Trial name
- MENO-ES (NCT07259525)
- Where
- Turkey (Türkiye)
- Volunteers
- 94 people
- Sponsor
- Eskisehir Osmangazi University
Anxiety Disorders,Generalized Anxiety Disorder
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD.
- Trial name
- NCT03924323
- Testing
- Escitalopram
- Where
- 39 sites in United States
- Volunteers
- 273 people
- Sponsor
- AbbVie
Anxiety
A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00390650
- Testing
- Saredutant
- Where
- 2 sites in United States, Canada
- Volunteers
- 366 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD
A placebo-controlled superiority design was used to evaluate the efficacy of 60 mg/ day or 120 mg/ day of Buagafuran capsules in the treatment of GAD
- Trial name
- BGFN-2022-02 (NCT06243640)
- Testing
- Buagafuran capsules, 15mg/ capsule, Buagafuran capsules mimic, 0mg/ capsule
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Depressive Symptoms, Generalized Anxiety
Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic
Background: COVID-19 (Corona Virus Disease 2019) is a virulent infectious disease with an incubation period ranging between 2-14 days.
- Trial name
- NCT04378257
- Testing
- Therapist Guided E-Therapy, Self-Help Therapy
- Volunteers
- 70 people
- Sponsor
- Sultan Qaboos University
Generalized Anxiety Disorder (GAD), Anxiety Disorders
EEG Study on Neurophysiological and Psychological Effects of Ericksonian Hypnotherapy in Generalized Anxiety Disorder
This study examines the neurophysiological and psychological effects of Ericksonian hypnotherapy in individuals diagnosed with Generalized Anxiety Disorder (GAD).
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety Disorders, Psychophysiological Disorders, Stress-Related Disorders
- Trial name
- EEG-HypnoGAD (NCT06811311)
- Testing
- Ericksonian Hypnotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Uskudar University
Bipolar Disorder, Panic Disorder
Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of ziprasidone monotherapy in comparison to placebo in the treatment of ambulatory bipolar disorder with co-morbid lifetime panic disorder or…
- Conditions
- Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
- Trial name
- PfizerAnxty (NCT01172652)
- Testing
- Ziprasidone
- Where
- 3 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- VA Palo Alto Health Care System
Generalized Anxiety
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00417118
- Testing
- Saredutant, Escitalopram
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 365 people
- Sponsor
- Sanofi
Anxiety Disorders
Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.
The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD).
- Trial name
- PLATINUM (NCT00314210)
- Testing
- Quetiapine SR
- Where
- 114 sites in United States, Australia and 9 more
- Volunteers
- 575 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Borderline Personality Disorder
Triage Survey for Psychiatry Research Eligibility
TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.
- Conditions
- Major Depressive Disorder, Borderline Personality Disorder, Generalized Anxiety Disorder
- Trial name
- TRIAGE-Psych (NCT05800925)
- Testing
- Survey
- Where
- 6 sites in United States
- Volunteers
- 20,000 people
- Sponsor
- Adams Clinical
Panic Disorder, Generalized Anxiety Disorder
Transdiagnostic Versus Diagnosis-specific Cognitive-behavioral Therapy
The primary aim of the pilot study is to investigate the feasibility of conducting a randomized controlled trial (RCT) comparing the effects of transdiagnostic and diagnosis-specific cognitive-behavioral therapy (CBT) for…
- Conditions
- Panic Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Obsessive-Compulsive Disorder
- Trial name
- NCT05249543
- Testing
- Unified protocol, Diagnosis-specific cognitive-behavioral therapy
- Where
- Sweden
- Volunteers
- 76 people
- Sponsor
- Karolinska Institutet
Generalized Anxiety Disorder
Treatment of Adults With Generalized Anxiety Disorder Using Glutamine
The objective of this randomized clinical trial is to examine the efficacy of L-glutamine for the treatment of generalized anxiety disorder compared versus placebo.
- Trial name
- NCT04274114
- Testing
- L Glutamine
- Where
- Mexico
- Volunteers
- 38 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Parkinson's Disease
Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease
The purpose of this study is to determine the safety of using a modified virus to transfer a gene called GAD into a region of the brain called the subthalamic nucleus in patients with advanced Parkinson's disease.
- Trial name
- NCT00195143
- Testing
- Surgical infusion of AAV-GAD into the subthalamic nucleus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Neurologix, Inc.
Anxiety Disorders
Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning
The purpose of this study is to increase researchers understanding of the biological basis of generalized anxiety disorder and social anxiety disorder.
- Trial name
- NCT00062517
- Where
- United States
- Volunteers
- 497 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Anxiety Disorders
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
This study will examine duloxetine compared with placebo and an active comparator in the treatment of generalized anxiety disorder.
- Trial name
- NCT00122850
- Testing
- Duloxetine, venlafaxine
- Where
- 19 sites in United States
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Generalized Anxiety Disorder
Qualitative Study of Student Financial Insecurity and Psychiatry
Since the COVID-19 pandemic, mental health disorders have increased significantly, particularly among young people. In France, the proportion of young people aged 18 to 25 suffering from depression almost doubled between 2017 and…
- Conditions
- Depressive Disorder, Generalized Anxiety Disorder, Suicidal Ideation
- Trial name
- QUALIPEPSY (NCT07719816)
- Testing
- Semi-structured interviews
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anxiety Disorder, Anxiety Disorders
Study Of Generalized Anxiety Disorder
This study is designed to evaluate the efficacy and safety in Generalized Anxiety Disorder patients
- Trial name
- NCT00135525
- Testing
- Paroxetine
- Sponsor
- GlaxoSmithKline
Autism, Asperger's Syndrome
Computer- Assisted Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
This study will examine the efficacy of a computerized cognitive behavioral therapy (CCBT) program for children with anxiety and autism spectrum disorders.
- Conditions
- Autism, Asperger's Syndrome, Generalized Anxiety Disorder, Social Phobia
- Trial name
- CCAL (NCT01565629)
- Testing
- Computer assisted cognitive behavioral therapy.
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Generalized Anxiety Disorder
Exercise Training for the Treatment of Generalized Anxiety Disorder
The purpose of this study is to compare the effects of 6 weeks of endurance or strength training and a wait list comparison condition on symptoms of Generalized Anxiety Disorder (GAD).
- Trial name
- NCT00953654
- Testing
- Strength Training, Endurance Training
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Georgia